ARTICLE SUMMARY:
Half of patients with heart failure—those with preserved ejection fraction—lack good therapeutic options. Corvia has developed an interatrial shunt that lowers left atrial pressure, which, in clinical trials with over one year of follow-up, has proven to be safe and effective in reducing symptoms of heart failure.
While great strides have been made in the treatment of heart failure, just about all of the innovation around interventional devices has been targeted to a patient population that represents only half of those suffering from the disease.
